Medcolcanna Organics signs strategic alliance agreement with DNA Genetics


News and research before you hear about it on CNBC et al. Claim your 1-week free trial for Street Insider Premium here.

Bogota, Colombia – (Newsfile Corp. – November 25, 2021) – Medcolcanna Organics Inc. (NEO: MCCN) (“Medcolcanna“,”MCCN“or the”Society“), a Canadian and globally integrated medicinal cannabis company with operations in Colombia, is pleased to announce the signing of a strategic alliance agreement with DNA Genetics, a California-based company with over 15 years of experience in the rapprochement to advance genetics in the cannabis industry.

The terms of the agreement will allow Medcolcanna to benefit from DNA Genetics’ extensive expertise in breeding, cultivation and phenotyping activities, and to use the exclusive and widely recognized high quality strains, brands and name. of DNA Genetics for the marketing of dried flower products worldwide.

MCCN will also license DNA Genetics seeds for export to its own customers, while the agreement opens up a new revenue stream by allowing Medcolcanna to produce seeds on behalf of DNA Genetics for its customers. The agreement also provides for advice and guidance on cultivation, post-harvest, processing and, in general, advice on cultivation of cannabis.

This new strategic alliance is just part of the cooperation between Medcolcanna and IHF (Industrial Hemp Farms) to create a low-cost, high-quality production supply chain in Colombia for the world.

MCCN has already signed with IHF one of the largest hemp flower supply contracts known to date and is working with proven and reliable counterparts around the world to secure sales of THC dried flowers.

Comment from MCCN CEO Felipe de la Vega:

“We are very happy to announce this agreement. Special thanks to our IHF business partners, who have worked with us on this strategy, brought their expertise and network to the cannabis industry in the United States and around the world and share our vision to focus on producing high quality (CBD and THC) flowers at low cost.

“This alliance is an important step for our access to the countries under negotiation, such as Germany, Poland, the United Kingdom and Israel, among others.”

Comment from DNA Genetics President Rezwan Khan:

“We are very pleased to announce our partnership with MCCN and to expand our presence in the Colombian market. Through this partnership, we will bring to Colombia some of the most unique cannabis genetics in DNA and have the ability to export our most sought after strains internationally. We look forward to seeing our partnership with Medcolcanna flourish in Colombia and countless other markets around the world ”,

About Medcolcanna

Medcolcanna is a vertically integrated Canadian medical cannabis company with fully licensed operations based in Colombia.

Led by a proven and successful management team, Medcolcanna has a growing number of facilities in optimal growth locations, positioning the company to become a global leader in the medical cannabis market.

About DNA genetics

DNA has its roots in Los Angeles and was founded in Amsterdam in 2004 by Don Morris and Aaron Yarkoni. Over the past decade, the company has built and organized a seasoned genetic library and developed proven standard operating procedures for genetic selection, reproduction and culture. In a world that is increasingly opening up to the commercial activity of cannabis, DNA is positioned to become the first truly geographically diversified company with multiple partnerships with leading producers and brands who have built their businesses and a Global presence using the “Powered by DNA” mockup. For more information, please visit

If you would like to receive press releases by email as soon as they are published, please sign up here: or write to [email protected].

Additional information about Medcolcanna can be found on its website at

Medcolcanna Investor Relations Contact: Chris Reid, CFO Carrera 49b # 93-62 Bogota, Colombia
Phone: +571 642-9113 E-mail: [email protected]

DNA Genetics media contact: Kate Pasterkiewicz – Global Corporate Development Associate – DNA Genetics [email protected]

Forward-looking statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this press release. .

Any statement involving discussions regarding predictions, expectations, beliefs, plans, projections, goals, assumptions, future events or performance, “anticipates” or “does not anticipate”, “plans”, “budget”, “planned”, ” foresees “,” considers “,” considers “,”, “intends to” or variations of these words and expressions or indicating that certain actions, events or results “may”, “could”, “would” , “Could” or “would” be considered to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Forward-looking statements are necessarily based on a number of estimates and assumptions which, although believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors that may cause actual results and future events differ materially from those expressed or implied. by such forward-looking statements. These factors include, but are not limited to, general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals for any proposed transaction, including those discussed herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Therefore, readers should not place undue reliance on the forward-looking statements and information contained in this press release.

Medcolcanna assumes no obligation to update any forward-looking statements of beliefs, opinions, projections or other factors, as they change, except as required by law.

To view the source version of this press release, please visit


Comments are closed.